• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重因子XI缺乏症患者未进行预防性治疗的白内障摘除术。

Cataract extraction without prophylactic treatment in patients with severe factor XI deficiency.

作者信息

Fabian Ido Didi, Sachs Dan, Moisseiev Joseph, Alhalel Amir, Grinbaum Aharon, Seligsohn Uri, Salomon Ophira

机构信息

The Goldschleger Eye Institute, Tel Aviv University, Tel Aviv, Israel.

出版信息

Am J Ophthalmol. 2009 Dec;148(6):920-4.e1. doi: 10.1016/j.ajo.2009.07.013. Epub 2009 Sep 5.

DOI:10.1016/j.ajo.2009.07.013
PMID:19733832
Abstract

PURPOSE

To assess the risks of intraoperative and postoperative bleeding associated with cataract extraction without prophylactic treatment in patients with severe factor XI (FXI) deficiency.

DESIGN

Prospective interventional case series.

SETTING

Single institute.

STUDY POPULATION

Consecutive unrelated patients with severe FXI deficiency who underwent cataract extraction under topical anesthesia, with a clear corneal incision, phacoemulsification, and implantation of a foldable posterior chamber intraocular lens (PCIOL) were enrolled. Patients with associated intraocular conditions that could complicate the surgery were excluded.

INTERVENTION

Cataract extraction without prophylactic treatment for the FXI deficiency.

MAIN OUTCOME MEASURES

Assessment of intraoperative and postoperative ocular bleeding and other related complications.

RESULTS

Seven patients ranging in age from 61 to 95 years (median, 79) underwent phacoemulsification and PCIOL implantation in 11 eyes. Five patients (71%) were homozygotes for type II mutation of the FXI gene (activity level of <1 U/dl), 1 patient was a homozygote for type III mutation (activity level of 11 U/dl), and 1 patient was a compound heterozygote for types II and III (activity level of 3 U/dl). Three of the patients (43%), all type II homozygotes, also had an inhibitor antibody to FXI. All 7 patients were followed for at least 1 week after the operation. The surgery was uneventful in all eyes, and neither major nor minor bleeding events were observed in any of the operated eyes during surgery and follow-up.

CONCLUSIONS

Cataract extraction by phacoemulsification in uncomplicated eyes can be performed safely without prophylactic treatment in patients with severe FXI deficiency with or without inhibitor antibodies against FXI.

摘要

目的

评估重度凝血因子 XI(FXI)缺乏患者在未进行预防性治疗的情况下进行白内障摘除术时术中及术后出血的风险。

设计

前瞻性干预性病例系列研究。

地点

单一机构。

研究人群

纳入连续的、无亲属关系的重度 FXI 缺乏患者,这些患者在表面麻醉下接受白内障摘除术,采用透明角膜切口、超声乳化术,并植入可折叠后房型人工晶状体(PCIOL)。排除伴有可能使手术复杂化的眼内疾病的患者。

干预措施

对 FXI 缺乏未进行预防性治疗的白内障摘除术。

主要观察指标

评估术中及术后眼部出血及其他相关并发症。

结果

7 例年龄在 61 至 95 岁(中位数为 79)的患者的 11 只眼睛接受了超声乳化术和 PCIOL 植入术。5 例患者(71%)为 FXI 基因 II 型突变纯合子(活性水平<1 U/dl),1 例患者为 III 型突变纯合子(活性水平为 11 U/dl),1 例患者为 II 型和 III 型复合杂合子(活性水平为 3 U/dl)。3 例患者(43%),均为 II 型纯合子,还存在 FXI 抑制性抗体。所有 7 例患者术后均至少随访 1 周。所有眼睛手术均顺利,在手术及随访期间,任何一只手术眼均未观察到重大或轻微出血事件。

结论

对于伴有或不伴有 FXI 抑制性抗体的重度 FXI 缺乏患者,在无并发症的眼中进行超声乳化白内障摘除术时,无需预防性治疗即可安全进行。

相似文献

1
Cataract extraction without prophylactic treatment in patients with severe factor XI deficiency.严重因子XI缺乏症患者未进行预防性治疗的白内障摘除术。
Am J Ophthalmol. 2009 Dec;148(6):920-4.e1. doi: 10.1016/j.ajo.2009.07.013. Epub 2009 Sep 5.
2
Phacoemulsification of cataract in patients receiving Coumadin therapy: ocular and hematologic risk assessment.接受香豆素治疗的患者白内障超声乳化术:眼部和血液学风险评估
Am J Ophthalmol. 2007 Nov;144(5):719-723. doi: 10.1016/j.ajo.2007.07.029. Epub 2007 Sep 17.
3
Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy.联合抗凝和抗血小板治疗患者行单纯超声乳化白内障吸除术的风险评估。
J Cataract Refract Surg. 2011 Aug;37(8):1434-8. doi: 10.1016/j.jcrs.2011.02.035. Epub 2011 Jun 17.
4
New observations on factor XI deficiency.关于因子 XI 缺乏症的新观察结果。
Haemophilia. 2004 Oct;10 Suppl 4:184-7. doi: 10.1111/j.1365-2516.2004.00992.x.
5
Evaluation of the need to discontinue antiplatelet and anticoagulant medications before cataract surgery.白内障手术前停用抗血小板和抗凝药物必要性的评估。
J Cataract Refract Surg. 2010 Jul;36(7):1115-9. doi: 10.1016/j.jcrs.2010.01.017.
6
Outcomes of cataract surgery in senile cataract patients at Siriraj Hospital: a prospective observational study.诗里拉吉医院老年白内障患者白内障手术的结果:一项前瞻性观察研究。
J Med Assoc Thai. 2005 Nov;88 Suppl 9:S82-8.
7
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.重组活化凝血因子VII和氨甲环酸在患有抑制性抗体的XI因子缺乏患者的大手术期间具有止血效果。
Thromb Haemost. 2009 Sep;102(3):487-92. doi: 10.1160/TH09-03-0172.
8
Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.联合氟轻松丙酮奈德眼内给药系统植入、超声乳化术及人工晶状体植入治疗严重葡萄膜炎。
Am J Ophthalmol. 2008 Oct;146(4):589-594. doi: 10.1016/j.ajo.2008.05.035. Epub 2008 Jul 17.
9
Incidence and functional outcome of phacoemulsification complicated by posterior capsular rupture.白内障超声乳化吸除术并发后囊膜破裂的发生率及功能转归
Klin Oczna. 2009;111(1-3):26-9.
10
Factor XI deficiency in Ashkenazi Jews in Israel.以色列阿什肯纳兹犹太人中的凝血因子XI缺乏症。
N Engl J Med. 1991 Jul 18;325(3):153-8. doi: 10.1056/NEJM199107183250303.

引用本文的文献

1
A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.治疗性因子 XI(a)抑制剂患者出血管理的建议。
J Thromb Haemost. 2022 Jan;20(1):32-38. doi: 10.1111/jth.15579. Epub 2021 Nov 21.
2
Hemophilia presenting as recurrent ocular hemorrhage.以反复眼部出血为表现的血友病。
GMS Ophthalmol Cases. 2020 Mar 18;10:Doc15. doi: 10.3205/oc000142. eCollection 2020.